Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders

Abstract

ClinicalTrials.gov Identifier: NCT02411123​​.

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings

“…Previous studies have presented data pointing to increased efficacy by incorporating pharmacogenetic testing in the management of patients diagnosed with depression. 21 , 23 Other studies also point to decreased adverse drug events, 22 , 25 lower health care utilization costs, 24 , 26 , 27 and increased adherence rates with pharmacogenetic-guided treatment. 27 Our model shows a potential annual cost savings of USD$3,962 per patient tested with NeuroIDgenetix.…”

“…NeuroIDgenetix ® testing is a promising tool in personalized medicine that has been shown to optimize medication management for depression or anxiety patients by using genetic factors and current drug regimen to determine variations in clinical response and side effects. 21 , 22 The NeuroIDgenetix test uses a genetic variant panel of 10 genes, along with concomitant medications, to make medication management recommendations based on gene–drug and drug–drug interactions for over 40 medications used in the treatment of depression and anxiety. This technology can help mental health providers predict medication response and appropriate dosing, leading to improved patient outcomes.…”

Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry

“…There are various factors that may also prompt testing, such as electronic health record (EHR) alerts, clinical decisions, consideration of medications with PGx verbiage, referral to a specialist, and unknown medication history. Currently, the extant data suggest that PGx testing may be obtained following 1 medication failure in patients with major depressive disorder (MDD) [26][27][28][29][30][31][32][33][34][35][36][37]. These data include multiple clinical trials from commercial testing companies, including 5 randomized controlled trials (RCTs) and 2 meta-analyses [26][27][28][29][30]32].…”

Perspectives of a pharmacist‐run pharmacogenomic service for depression in interdisciplinary family medicine practices

“…Additionally, pharmacists have the foundational education and training to interpret pharmacogenomic results given their expertise in pharmacokinetics, drug metabolism, and medication adverse effect profiles . Pharmacists may use pharmacogenomic results to tailor treatment plans for patients with depression to reduce the risk of adverse effects and increase drug tolerability, ultimately improving the patient experience …”

“…35,36 Pharmacists may use pharmacogenomic results to tailor treatment plans for patients with depression to reduce the risk of adverse effects and increase drug tolerability, ultimately improving the patient experience. 37,38 As shown in the results of this project, pharmacists integrated into the primary care setting are the preferred team member to implement pharmacogenomics programs given their extensive medication training and knowledge. As the field of pharmacogenomics continues to grow, and physicians view pharmacists as integral team members, pharmacists working in the primary care setting should seek out continuing education opportunities to ensure they are well-positioned to integrate pharmacogenomics into their practice sites when the opportunity arises.…”